NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
Globe Newswire•07/10/2026•09:43 ET
0
Key Highlights
- ➤Revolution Medicines’ Rasonque gains FDA approval for metastatic pancreatic adenocarcinoma
- ➤Rasonque median overall survival reaches 13.2 months versus 6.7 months with chemotherapy
- ➤Johnson & Johnson combination cuts myeloma progression-or-death risk by 89%
- ➤Genmab-AbbVie epcoritamab regimen cuts first-line lymphoma progression-or-death risk by 51%
- ➤NeOnc NEO100 Phase 2a shows 26.09-month median survival in recurrent glioma
DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com)-- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?
A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These developments span different levels of clinical evidence, from exploratory Phase 2 findings to randomized Phase 3 results and an FDA approval. SEC
Get started
Create a free account to read the full story.